Clinical Endpoint– tag –
-
Nurix Therapeutics’ Bexobrutideg Shows 83% ORR and 22.1 Months PFS in Relapsed/Refractory CLL/SLL Phase 1 Study
Nurix Therapeutics USA Overview Nurix Therapeutics reported updated clinical data from its NX-5948-301 Phase 1a/1b study, showing durable responses and a favorable tolerability profile for bexobrutideg in relapsed/refractory CLL/SLL pati... -
Merck/Kelun-Biotech ADC Candidate Sac-TMT Demonstrates Superior Progression-Free Survival Over Chemotherapy in China Phase 3 Lung Cancer Study
Endpoints News USA Overview Merck's partner Kelun-Biotech announced positive Phase 3 study results in China for sac-TMT, an experimental antibody-drug conjugate (ADC). In non-squamous non-small cell lung cancer, sac-TMT combined with imm... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
ADC Therapeutics Completes Enrollment for LOTIS-7 Phase 1b Trial of Zynlonta-Glofitamab Combination, Reporting Interim 89.8% ORR in Relapsed/Refractory DLBCL Patients
BioPharm International Switzerland Overview ADC Therapeutics has completed patient enrollment for the Phase 1b LOTIS-7 trial, evaluating the combination of its CD19-targeted antibody-drug conjugate (ADC) Zynlonta with the bispecific anti... -
FDA Greenlights Breakthrough TNBC Therapies, First-in-Class Hypertriglyceridemia Drug, and New Breast Cancer Maintenance Regimen
FDA USA Overview On June 24, 2026, the U.S. FDA announced pivotal approvals across several cancer and metabolic disease indications, introducing significant new therapeutic options. These include a breakthrough for triple-negative breast...
12